Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.723 USD | -0.27% | +0.98% | -29.11% |
Apr. 17 | Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board | CI |
Apr. 09 | Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.11% | 5.1M | |
-2.67% | 102B | |
+2.02% | 96.29B | |
+1.86% | 22.18B | |
-15.33% | 21.2B | |
-8.77% | 18.31B | |
-38.74% | 17.38B | |
-14.17% | 16.36B | |
+5.55% | 13.97B | |
+32.97% | 12.17B |
- Stock Market
- Equities
- LIPO Stock
- News Lipella Pharmaceuticals Inc.
- Lipella Pharmaceuticals Says US FDA Approves IND Status for LP-310 for Oral Lichen Planus; Shares Surge